109 related articles for article (PubMed ID: 33523474)
1. How Semiphysiological Population Pharmacokinetic Modeling Incorporating Active Hepatic Uptake Supports Phase II Dose Selection of RO7049389, A Novel Anti-Hepatitis B Virus Drug.
Cosson V; Feng S; Jaminion F; Lemenuel-Diot A; Parrott N; Paehler A; Bo Q; Jin Y
Clin Pharmacol Ther; 2021 Apr; 109(4):1081-1091. PubMed ID: 33523474
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial.
Yuen MF; Zhou X; Gane E; Schwabe C; Tanwandee T; Feng S; Jin Y; Triyatni M; Lemenuel-Diot A; Cosson V; Xue Z; Kazma R; Bo Q
Lancet Gastroenterol Hepatol; 2021 Sep; 6(9):723-732. PubMed ID: 34237271
[TBL] [Abstract][Full Text] [Related]
3. A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants.
Feng S; Gane E; Schwabe C; Zhu M; Triyatni M; Zhou J; Bo Q; Jin Y
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32839221
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the safety, tolerability, and pharmacokinetics of RO7049389 in healthy Chinese volunteers.
Wu X; Feng S; Zhang J; Zhang W; Zhang Y; Zhu M; Triyatni M; Zhao N; Bo Q; Jin Y
Clin Transl Sci; 2022 Jan; 15(1):195-203. PubMed ID: 34562067
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the drug disposition of RO7049389 with in vitro data and human mass balance supported by physiologically based pharmacokinetic modelling.
Zhang Y; Umehara K; Romeo AA; Singh N; Cantrill C; Savage M; Chen E; Zhang W; Parrot NJ; Paehler A
Br J Clin Pharmacol; 2023 Oct; 89(10):3079-3091. PubMed ID: 37264516
[TBL] [Abstract][Full Text] [Related]
6. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U
Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752
[TBL] [Abstract][Full Text] [Related]
7. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.
Gish RG; Leung NW; Wright TL; Trinh H; Lang W; Kessler HA; Fang L; Wang LH; Delehanty J; Rigney A; Mondou E; Snow A; Rousseau F
Antimicrob Agents Chemother; 2002 Jun; 46(6):1734-40. PubMed ID: 12019083
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects.
Huntjens DRH; Ouwerkerk-Mahadevan S; Brochot A; Rusch S; Stevens M; Verloes R
Clin Pharmacokinet; 2017 Nov; 56(11):1331-1342. PubMed ID: 28238203
[TBL] [Abstract][Full Text] [Related]
9. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
10. A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B.
Sokal EM; Roberts EA; Mieli-Vergani G; McPhillips P; Johnson M; Barber J; Dallow N; Boxall E; Kelly D
Antimicrob Agents Chemother; 2000 Mar; 44(3):590-7. PubMed ID: 10681323
[TBL] [Abstract][Full Text] [Related]
11. Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.
Polepally AR; Mensing S; Khatri A; Beck D; Liu W; Awni WM; Menon RM; Dutta S
Clin Pharmacokinet; 2016 Sep; 55(9):1091-101. PubMed ID: 27000758
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects.
Vandenbossche J; Jessner W; van den Boer M; Biewenga J; Berke JM; Talloen W; De Zwart L; Snoeys J; Yogaratnam J
Adv Ther; 2019 Sep; 36(9):2450-2462. PubMed ID: 31267367
[TBL] [Abstract][Full Text] [Related]
13. Effect of Plasma Protein Binding on the Anti-Hepatitis B Virus Activity and Pharmacokinetic Properties of NVR 3-778.
Helsen N; Vervoort T; Vandenbossche J; Lenz O; Monshouwer M; Pauwels F; Snoeys J
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30181376
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous Assessment of Clearance, Metabolism, Induction, and Drug-Drug Interaction Potential Using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus Inhibitor.
Kratochwil NA; Triyatni M; Mueller MB; Klammers F; Leonard B; Turley D; Schmaler J; Ekiciler A; Molitor B; Walter I; Gonsard PA; Tournillac CA; Durrwell A; Marschmann M; Jones R; Ullah M; Boess F; Ottaviani G; Jin Y; Parrott NJ; Fowler S
J Pharmacol Exp Ther; 2018 May; 365(2):237-248. PubMed ID: 29453199
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus.
Lam AM; Espiritu C; Vogel R; Ren S; Lau V; Kelly M; Kuduk SD; Hartman GD; Flores OA; Klumpp K
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373799
[TBL] [Abstract][Full Text] [Related]
16. NIH consensus development statement on management of hepatitis B.
Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT
NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020
[TBL] [Abstract][Full Text] [Related]
17. Coinfection of Schistosoma Species with Hepatitis B or Hepatitis C Viruses.
Abruzzi A; Fried B; Alikhan SB
Adv Parasitol; 2016; 91():111-231. PubMed ID: 27015949
[TBL] [Abstract][Full Text] [Related]
18. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B.
Yuen MF; Kim J; Kim CR; Ngai V; Yuen JC; Min C; Kang HM; Shin BS; Yoo SD; Lai CL
Antivir Ther; 2006; 11(8):977-83. PubMed ID: 17302367
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor.
Mallalieu NL; Rahimy MH; Crowley CA; Appleman JR; Smith PF; Freddo JL
Clin Ther; 2014 Dec; 36(12):2047-2063.e3. PubMed ID: 25456558
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model.
Weber O; Schlemmer KH; Hartmann E; Hagelschuer I; Paessens A; Graef E; Deres K; Goldmann S; Niewoehner U; Stoltefuss J; Haebich D; Ruebsamen-Waigmann H; Wohlfeil S
Antiviral Res; 2002 May; 54(2):69-78. PubMed ID: 12062392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
